Amyotrophic Lateral Sclerosis - Epidemiology Forecast to 2023, New Report Launched

Amyotrophic lateral sclerosis (ALS) is a rare, but fatal, progressive neurodegenerative disease that affects the nerve cells in the brain and the spinal cord (NINDS, 2013). ALS is often referred to as ""Lou Gehrig's Disease"" after the famous baseball player who was diagnosed with it in the 1930s (Mayo Clinic, 2014). ALS severely impacts physical functioning and initially presents with muscle twitching, weakness in an arm or leg, or sometimes with slurring of speech. Eventually, people with ALS lose their ability to control the muscles needed to move, speak, eat, and breathe, which ultimately leads to death (Mayo Clinic, 2014). Globally, ALS accounts for approximately one in every 800 deaths (Majoor-Krakauer et al., 2003). The progressively degenerative course of the condition is a great burden for both patients and caregivers, as well as for society (Majoor-Krakauer et al., 2003). ALS usually occurs in people age ≥40 years, and more often in men than women. ALS has a worldwide incidence of about two cases per 100,000 population, and a prevalence ranging between four and seven cases per 100,000 population (Eisen, 2002).

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for ALS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). In addition, the report includes a 10-year epidemiological forecast (2013–2023) for the diagnosed prevalent cases of ALS segmented by sex and age (in 10-year age groups, beginning at age 40 years and ending at age ≥80 years). To forecast the diagnosed prevalent cases of ALS in the 7MM, GlobalData epidemiologists used only country-specific studies that provided the diagnosed prevalence of ALS using uniform diagnostic criteria based on the El Escorial criteria or the International Classification of Diseases, Ninth Revision (ICD-9), criteria (ICD-9 code for ALS = 335.2), to allow for a meaningful comparison of the diagnosed prevalent cases of ALS in these markets.

The diagnosed prevalent cases of ALS in the 7MM will increase from 32,698 cases in 2013 to 37,122 cases in 2023, at a growth rate of 13.5% over the forecast period. Throughout the forecast period, the US will have the highest numbers of diagnosed prevalent cases of ALS, followed by Japan, where the two markets combined will constitute more than 50% of the diagnosed prevalent cases in the 7MM. GlobalData epidemiologists attribute the growth in the diagnosed prevalent cases of ALS in the 7MM to the changing population demographics in the respective markets.

Know more about this report at: http://mrr.cm/ZGs

Find other Pharma and Healthcare Reports at : 

http://www.marketresearchreports.com/pharma-healthcare